{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:35:46Z","timestamp":1789428946010,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"publisher","award":["FIS\/IMSS\/PRIO\/15\/048, FIS\/IMSS\/PROT\/PRIO\/18\/080"],"award-info":[{"award-number":["FIS\/IMSS\/PRIO\/15\/048, FIS\/IMSS\/PROT\/PRIO\/18\/080"]}],"id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["FORDECYT-PRONACES:303019, FORDECYT-PRONACES-377883-2020"],"award-info":[{"award-number":["FORDECYT-PRONACES:303019, FORDECYT-PRONACES-377883-2020"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Advances in the understanding of the pathobiology of childhood B-cell acute lymphoblastic leukemia (B-ALL) have led towards risk-oriented treatment regimens and markedly improved survival rates. However, treatment-related toxicities remain a major cause of mortality in developing countries. One of the most common adverse effects of chemotherapy in B-ALL is the hematologic toxicity, which may be related to genetic variants in membrane transporters that are critical for drug absorption, distribution, and elimination. In this study we detected genetic variants present in a selected group genes of the <jats:italic>ABC<\/jats:italic> and <jats:italic>SLC<\/jats:italic> families that are associated with the risk of high-grade hematologic adverse events due to chemotherapy treatment in a group of Mexican children with B-ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Next generation sequencing (NGS) was used to screen six genes of the ABC and seven genes of the SLC transporter families, in a cohort of 96 children with B-ALL. The grade of hematologic toxicity was classified according to the National Cancer Institute\u2019s Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, Subsequently, two groups of patients were formed: the null\/low-grade (grades 1 and 2) and the high-grade (grades 3 to 5) adverse events groups. To determine whether there is an association between the genetic variants and high-grade hematologic adverse events, logistic regression analyses were performed using co-dominant, dominant, recessive, overdominant and log-additive inheritance models. Odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found two types of associations among the genetic variants identified as possible predictor factors of hematologic toxicity. One group of variants associated with high-grade toxicity risk: <jats:italic>ABCC1<\/jats:italic> rs129081; <jats:italic>ABCC4<\/jats:italic> rs227409; <jats:italic>ABCC5<\/jats:italic> rs939338, rs1132776, rs3749442, rs4148575, rs4148579 and rs4148580; and another group of protective variants that includes <jats:italic>ABCC1<\/jats:italic> rs212087 and rs212090; <jats:italic>SLC22A6<\/jats:italic> rs4149170, rs4149171 and rs955434.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There are genetic variants in the <jats:italic>SLC<\/jats:italic> and <jats:italic>ABC<\/jats:italic> transporter families present in Mexican children with B-ALL that can be considered as potential risk markers for hematologic toxicity secondary to chemotherapeutic treatment, as well as other protective variants that may be useful in addition to conventional risk stratification for therapeutic decision making in these highly vulnerable patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1276352","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T18:28:12Z","timestamp":1704911292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Deyanira","family":"Escalante-Bautista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Cerecedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva","family":"Jim\u00e9nez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gonz\u00e1lez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gayt\u00e1n-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"N\u00fa\u00f1ez-Enr\u00edquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Alejandro","family":"Sep\u00falveda-Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"De Ita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Jim\u00e9nez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"S\u00e1nchez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minerva","family":"Mata-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Refugio","family":"Torres-Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alfonso","family":"Mart\u00edn-Trejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Victoria","family":"Flores-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda de Lourdes","family":"Guti\u00e9rrez-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Elizabeth","family":"Merino-Pasaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Anastacia","family":"Sol\u00eds-Labastida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Raquel","family":"Miranda-Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Alicia","family":"Hern\u00e1ndez-Ech\u00e1urregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Orozco-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Flores-Lujano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Luisa","family":"P\u00e9rez-Sald\u00edvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mej\u00eda-Arangur\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayde\u00e9","family":"Rosas-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MPH.0b013e318162bcdc","article-title":"The age incidence of childhood B-cell precursor acute lymphoblastic leukemia in Mexico City","volume":"30","author":"Bernaldez-Rios","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.414","article-title":"How can we improve on the already impressive results in pediatric ALL","volume":"2015","author":"Thomas","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091502","article-title":"Pharmacogenomics in pediatric oncology: review of gene drug associations for clinical use","volume":"17","author":"Mlakar","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/23288604.2021.1914897","article-title":"Acute lymphoblastic leukaemia survival in children covered by seguro popular in Mexico: A national comprehensive analysis 2005-2017","volume":"7","author":"Mu\u00f1oz-Aguirre","year":"2021","journal-title":"Health Syst Reform"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.757464","article-title":"The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematologic Malignancies: A systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133113","article-title":"Solute carrier nucleoside transporters in hematopoiesis and hematologic drug toxicities: a perspective","volume":"14","author":"Ali","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/08880018.2016.1276235","article-title":"Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia","volume":"34","author":"Yeoh","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.12688\/f1000research.10768.1","article-title":"Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy","volume":"6","author":"Schmiegelow","year":"2017","journal-title":"F1000Research"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.251","article-title":"Crisis management in the treatment of childhood acute lymphoblastic leukemia: Putting right what can go wrong (emergency complications of disease and treatment)","volume":"2017","author":"Hough","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5b00753","article-title":"Conformational changes of the antibacterial peptide ATP binding cassette transporter mcjD revealed by molecular dynamics simulations","volume":"54","author":"Gu","year":"2015","journal-title":"Biochemistry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/srep16724","article-title":"Tracing the structural evolution of eukaryotic ATP binding cassette transporter superfamily","volume":"5","author":"Xiong","year":"2015","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1124\/mol.114.096792","article-title":"ATP binding cassette transporter structure changes detected by intramolecular fluorescence energy transfer for high-throughput screening","volume":"88","author":"Iram","year":"2015","journal-title":"Mol Pharmacol"},{"key":"B15","article-title":"Pattern of ABCC transporter gene expression in pediatric patients with relapsed acute lymphoblastic leukemia","volume":"8","author":"Mehrvar","year":"2019","journal-title":"Rep Biochem Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.621573","article-title":"In vitro reassembly of the ribose ATP-binding cassette transporter reveals a distinct set of transport complexes","volume":"290","author":"Clifton","year":"2015","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.175","article-title":"Profiling solute carrier transporters in the human blood-brain barrier","volume":"96","author":"Geier","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e328343dd93","article-title":"PharmGKB summary: methotrexate pathway","volume":"21","author":"Mikkelsen","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do","volume":"14","author":"Nigam","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12226","article-title":"Implementation of TPMT testing","volume":"77","author":"Lennard","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25485","article-title":"Optimizing thiopurine dosing based on TPMT and NUDT15 genotypes: It takes two to tango","volume":"94","author":"Koutsilieri","year":"2019","journal-title":"Am J Hematol"},{"key":"B22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26366","article-title":"The burden of childhood cancer in Mexico: Implications for low- and middle-income countries","volume":"64","author":"Rivera-Luna","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11912-021-01043-9","article-title":"Childhood acute leukemias in developing nations: successes and challenges","volume":"23","author":"Zapata-Tarr\u00e9s","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26871","article-title":"An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001","volume":"65","author":"Kahn","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0376-z","article-title":"Pharmacogenetic predictors of treatment-related toxicity among children with acute lymphoblastic leukemia","volume":"12","author":"Maxwell","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"B27","article-title":"Mercaptopurine Therapy and TPMT and NUDT15 Genotype","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-021-00287-3","article-title":"Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico","volume":"74","author":"Texis","year":"2022","journal-title":"Pharmacol Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790112683","article-title":"Pharmacogenetics of drug transporters","volume":"16","author":"Franke","year":"2010","journal-title":"Curr Pharm Des"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/tpj.2015.83","article-title":"Pharmacogenetics and induction\/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol","volume":"17","author":"Franca","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/03602530801952617","article-title":"Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2)","volume":"40","author":"Gradhand","year":"2008","journal-title":"Drug Metab Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt008","article-title":"Genetic variability in the multidrug resistance associated protein-1 (ABCC1\/MRP1) predicts hematologic toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)","volume":"24","author":"Vulsteke","year":"2013","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000428","article-title":"Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia","volume":"31","author":"G\u00e1ndara-Mireles","year":"2021","journal-title":"Pharmacogenet Genomics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04163-7","article-title":"Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia","volume":"99","author":"Kunadt","year":"2020","journal-title":"Ann Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2021.1973628","article-title":"ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia","volume":"39","author":"Fan","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2217\/PGS.15.62","article-title":"Genetic variants in 6- mercaptopurine pathway as potential factors of hematologic toxicity in acute lymphoblastic leukemia patients","volume":"16","author":"Hareedy","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6790","article-title":"Transporter-mediated protection against thiopurine-induced hematopoietic toxicity","volume":"68","author":"Krishnamurthy","year":"2008","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2017.12","article-title":"Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia","volume":"8","author":"Tanaka","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190329141003","article-title":"Methotrexate disposition in pediatric patients with acute lymphoblastic leukemia: what have we learnt from the genetic variants of drug transporters","volume":"25","author":"Hu","year":"2019","journal-title":"Curr Pharm Des"},{"key":"B40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/tpj.2015.63","article-title":"Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicitym in survivors of childhood acute lymphoblastic leukemia","volume":"17","author":"Krajinovic","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"B41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/PGPM.S239602","article-title":"Implementation of pharmacogenetics to individualize treatment regimens for children with acute lymphoblastic leukemia","volume":"13","author":"Maamari","year":"2020","journal-title":"Pharmgenomics Pers Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24505","article-title":"Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children","volume":"60","author":"Visscher","year":"2013","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1276352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T18:28:17Z","timestamp":1704911297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1276352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":42,"alternative-id":["10.3389\/fonc.2023.1276352"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1276352","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"article-number":"1276352"}}